Skin Reaction with Facial Erythema

Sorafenib (NexavarⓇ, BAY 43-9006) is a novel, orally administered multi-kinase inhibitor that has recently been approved for the treatment of metastatic renal cell car-cinoma. It is also used to delay disease progression in patients with advanced solid organ malignancies and metastatic melanoma. Sorafenib is associated with a relatively high incidence of dermatologic adverse events. The commonly occurring dermatologic adverse events associated with sorafenib include hand-foot skin reaction, facial erythema, splinter subungual hemorrhages, alopecia, pruritus and xerosis. We report here on a case of a 50-year-old man who was diagnosed with metastatic hepatocellular carcinoma. He developed both facial ery-thema and hand-foot skin reaction after the administration of sorafenib. (Ann Dermatol 23(1) 119∼122, 2011)-Keywords-Facial erythema, Hand-foot skin reaction, Sorafeni